交易 Kaleido Biosciences, Inc. - KLDO CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.05 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Apr 14, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Apr 13, 2022 | 0.39 | 0.00 | 0.00% | 0.39 | 0.47 | 0.38 |
Apr 8, 2022 | 0.40 | -0.24 | -37.50% | 0.64 | 0.64 | 0.38 |
Apr 7, 2022 | 1.46 | -0.01 | -0.68% | 1.47 | 1.55 | 1.42 |
Apr 6, 2022 | 1.46 | -0.02 | -1.35% | 1.48 | 1.48 | 1.42 |
Apr 5, 2022 | 1.50 | -0.09 | -5.66% | 1.59 | 1.62 | 1.48 |
Apr 4, 2022 | 1.59 | -0.14 | -8.09% | 1.73 | 1.73 | 1.54 |
Apr 1, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.70 | 1.58 |
Mar 31, 2022 | 1.60 | -0.08 | -4.76% | 1.68 | 1.72 | 1.55 |
Mar 30, 2022 | 1.69 | -0.14 | -7.65% | 1.83 | 1.83 | 1.69 |
Mar 29, 2022 | 1.70 | 0.02 | 1.19% | 1.68 | 1.77 | 1.60 |
Mar 28, 2022 | 1.60 | -0.13 | -7.51% | 1.73 | 1.73 | 1.50 |
Mar 25, 2022 | 1.64 | -0.10 | -5.75% | 1.74 | 1.74 | 1.63 |
Mar 24, 2022 | 1.74 | 0.00 | 0.00% | 1.74 | 1.76 | 1.68 |
Mar 23, 2022 | 1.74 | 0.01 | 0.58% | 1.73 | 1.81 | 1.73 |
Mar 22, 2022 | 1.75 | 0.10 | 6.06% | 1.65 | 1.75 | 1.65 |
Mar 21, 2022 | 1.63 | -0.05 | -2.98% | 1.68 | 1.68 | 1.55 |
Mar 18, 2022 | 1.67 | 0.14 | 9.15% | 1.53 | 1.71 | 1.53 |
Mar 17, 2022 | 1.56 | 0.14 | 9.86% | 1.42 | 1.57 | 1.42 |
Mar 16, 2022 | 1.42 | 0.04 | 2.90% | 1.38 | 1.42 | 1.31 |
Kaleido Biosciences, Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
总收入 | 1.104 | 0.975 | 0 | 0 | 0 |
总营业费用 | 88.771 | 79.849 | 87.24 | 60.683 | 27.03 |
销售/一般/行政费用,总计 | 20.968 | 23.882 | 22.428 | 18.621 | 6.038 |
研究与开发 | 67.803 | 55.967 | 64.232 | 42.062 | 20.992 |
营业收入 | -87.667 | -78.874 | -87.24 | -60.683 | -27.03 |
利息收入(费用),非经营净值 | -2.766 | -2.553 | 0.968 | -0.805 | -0.512 |
其他,净值 | 0.145 | -0.193 | -0.059 | -0.256 | -0.017 |
税前净收入 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
税后净收入 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
未计算非常项目前的净收益 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
净收入 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
普通股股东可获收益 (不含非经常性项目) | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
普通股股东可获收益 (含非經常性項目) | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
摊薄净收入 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
摊薄后加权平均股 | 41.86 | 33.4502 | 25.7033 | 29.3948 | 29.3948 |
扣除特别项目的每股摊薄盈利 | -2.1569 | -2.44004 | -3.35876 | -2.10051 | -0.93755 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
每股正常摊薄盈利 | -2.1569 | -2.44004 | -3.33619 | -2.10051 | -0.93755 |
异常费用(收入) | 0 | 0.58 | |||
收入 | 1.104 | 0.975 |
Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
---|---|---|---|---|---|
总收入 | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
收入 | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
总营业费用 | 20.191 | 22.517 | 23.418 | 22.645 | 19.543 |
销售/一般/行政费用,总计 | 4.617 | 5.106 | 5.785 | 5.46 | 5.205 |
研究与开发 | 15.574 | 17.411 | 17.633 | 17.185 | 14.338 |
异常费用(收入) | 0 | ||||
营业收入 | -19.699 | -22.413 | -23.207 | -22.348 | -19.3 |
利息收入(费用),非经营净值 | -0.705 | -0.692 | -0.681 | -0.688 | -0.713 |
其他,净值 | 0.132 | 0.02 | -0.001 | -0.006 | -0.003 |
税前净收入 | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
税后净收入 | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
未计算非常项目前的净收益 | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
净收入 | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
普通股股东可获收益 (不含非经常性项目) | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
普通股股东可获收益 (含非經常性項目) | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
摊薄净收入 | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
摊薄后加权平均股 | 42.5995 | 42.5776 | 42.5386 | 39.6926 | 35.9841 |
扣除特别项目的每股摊薄盈利 | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
每股正常摊薄盈利 | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 42.311 | 48.721 | 73.279 | 76.243 | 28.551 |
现金和短期投资 | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
现金等价物 | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
应收账款总额,净额 | 0.005 | 0.045 | |||
Prepaid Expenses | 3.583 | 2.499 | 2.038 | 0.152 | 0.05 |
Total Assets | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
Property/Plant/Equipment, Total - Net | 5.665 | 8.462 | 6.742 | 4.693 | 1.975 |
Property/Plant/Equipment, Total - Gross | 11.136 | 11.955 | 9.281 | 5.914 | 2.406 |
Accumulated Depreciation, Total | -5.471 | -3.493 | -2.539 | -1.221 | -0.431 |
Other Long Term Assets, Total | 2.161 | 2.161 | 2.285 | 4.389 | 0.221 |
Total Current Liabilities | 29.682 | 16.659 | 10.377 | 11.301 | 3.854 |
Accounts Payable | 5.67 | 5.389 | 2.016 | 3.442 | 0.864 |
Accrued Expenses | 6.686 | 7.356 | 7.086 | 7.406 | 2.615 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 16.144 | 2.634 | 0.068 | 0.091 | 0.104 |
Other Current Liabilities, Total | 1.182 | 1.28 | 1.207 | 0.362 | 0.271 |
Total Liabilities | 39.53 | 38.848 | 33.423 | 28.343 | 21.932 |
Total Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
Other Liabilities, Total | 4.298 | 3.814 | 2.655 | 2.211 | 3.268 |
Total Equity | 10.607 | 20.496 | 48.883 | 56.982 | 8.815 |
Preferred Stock - Non Redeemable, Net | 153.226 | 52.494 | |||
Common Stock | 0.043 | 0.036 | 0.03 | 0.006 | 0.005 |
Additional Paid-In Capital | 375.031 | 294.639 | 241.412 | 9.978 | 0.8 |
Retained Earnings (Accumulated Deficit) | -364.467 | -274.179 | -192.559 | -106.228 | -44.484 |
Total Liabilities & Shareholders’ Equity | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
Total Common Shares Outstanding | 42.596 | 36.0228 | 30.1278 | 29.3948 | 29.3948 |
Redeemable Preferred Stock | 0 | 0 | |||
Other Current Assets, Total | 0.254 |
Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
---|---|---|---|---|---|
流动资产总额 | 42.311 | 58.304 | 74.603 | 95.032 | 48.721 |
现金和短期投资 | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
现金等价物 | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
Prepaid Expenses | 3.583 | 2.647 | 2.624 | 2.67 | 2.499 |
Total Assets | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
Property/Plant/Equipment, Total - Net | 5.665 | 7.339 | 7.526 | 7.833 | 8.462 |
Property/Plant/Equipment, Total - Gross | 11.136 | 12.482 | 12.165 | 11.889 | 11.955 |
Accumulated Depreciation, Total | -5.471 | -5.143 | -4.639 | -4.056 | -3.493 |
Other Long Term Assets, Total | 2.161 | 2.161 | 2.161 | 2.161 | 2.161 |
Total Current Liabilities | 29.682 | 19.261 | 12.269 | 12.873 | 16.659 |
Accounts Payable | 5.67 | 3.559 | 2.695 | 2.412 | 5.389 |
Accrued Expenses | 6.686 | 8.681 | 5.014 | 4.403 | 7.356 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 16.144 | 6.384 | 3.667 | 4.759 | 2.634 |
Other Current Liabilities, Total | 1.182 | 0.637 | 0.893 | 1.299 | 1.28 |
Total Liabilities | 39.53 | 38.604 | 34.024 | 33.252 | 38.848 |
Total Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
Other Liabilities, Total | 4.298 | 4.211 | 4.078 | 3.946 | 3.814 |
Total Equity | 10.607 | 29.2 | 50.266 | 71.774 | 20.496 |
Common Stock | 0.043 | 0.043 | 0.043 | 0.042 | 0.036 |
Additional Paid-In Capital | 375.031 | 373.352 | 371.333 | 368.953 | 294.639 |
Retained Earnings (Accumulated Deficit) | -364.467 | -344.195 | -321.11 | -297.221 | -274.179 |
Total Liabilities & Shareholders’ Equity | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
Total Common Shares Outstanding | 42.596 | 42.5801 | 42.5714 | 42.4832 | 36.0228 |
Redeemable Preferred Stock | 0 | 0 | |||
Other Current Assets, Total | 0.254 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
经营活动产生的现金 | -77.094 | -61.518 | -75.796 | -46.316 | -22.495 |
经营活动产生的现金 | 2.358 | 1.823 | 1.318 | 0.792 | 0.316 |
非现金物品 | 11.099 | 13.728 | 10.433 | 8.14 | 0.738 |
已付现金利息 | 2.133 | 1.925 | 0.881 | 0.943 | 0.343 |
营运资金的变化 | -0.263 | 4.551 | -1.216 | 6.496 | 4.01 |
投资活动产生的现金 | -0.691 | -4.024 | -3.586 | -3.002 | -1.406 |
资本支出 | -1.129 | -4.024 | -3.586 | -3.002 | -1.406 |
融资活动产生的现金 | 70.037 | 40.399 | 74.642 | 98.907 | 49.736 |
融资现金流项目 | -0.359 | -0.079 | -1.158 | -1.84 | 0 |
股票的发行(报废),净额 | 70.396 | 40.546 | 68.391 | 100.852 | 39.86 |
债务的发行(退还),净额 | 0 | -0.068 | 7.409 | -0.105 | 9.876 |
现金净变化 | -7.748 | -25.143 | -4.74 | 49.589 | 25.835 |
其他投资现金流量项目,总计 | 0.438 |
Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
---|---|---|---|---|---|
Net income/Starting Line | -90.288 | -70.016 | -46.931 | -23.042 | -81.62 |
Cash From Operating Activities | -77.094 | -59.934 | -44.057 | -23.974 | -61.518 |
Cash From Operating Activities | 2.358 | 1.754 | 1.16 | 0.577 | 1.823 |
Non-Cash Items | 11.099 | 9.331 | 7.146 | 4.603 | 13.728 |
Cash Interest Paid | 2.133 | 1.601 | 1.064 | 0.526 | 1.925 |
Changes in Working Capital | -0.263 | -1.003 | -5.432 | -6.112 | 4.551 |
Cash From Investing Activities | -0.691 | -0.693 | -0.262 | -0.03 | -4.024 |
Capital Expenditures | -1.129 | -0.693 | -0.262 | -0.03 | -4.024 |
Cash From Financing Activities | 70.037 | 70.062 | 70.076 | 70.144 | 40.399 |
Financing Cash Flow Items | -0.359 | -0.329 | -0.31 | -0.186 | -0.079 |
Issuance (Retirement) of Stock, Net | 70.396 | 70.391 | 70.386 | 70.33 | 40.546 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -0.068 | |
Net Change in Cash | -7.748 | 9.435 | 25.757 | 46.14 | -25.143 |
Other Investing Cash Flow Items, Total | 0.438 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Menichella (Daniel L.) | Individual Investor | 0.2996 | 127700 | 107700 | 2022-03-31 | MED |
Duke (William E. Jr.) | Individual Investor | 0.1598 | 68115 | 68115 | 2022-03-31 | LOW |
Korn (Jerald) | Individual Investor | 0.1215 | 51803 | 51803 | 2022-03-31 | |
Melas-Kyriazi (Theo) | Individual Investor | 0.0782 | 33333 | 0 | 2022-03-31 | LOW |
Quinn (Anthony G) | Individual Investor | 0.0741 | 31603 | 0 | 2022-03-31 | LOW |
Northern Trust Global Investments | Investment Advisor | 0.0334 | 14235 | 14235 | 2022-12-31 | LOW |
DWS Investments UK Limited | Investment Advisor | 0.0244 | 10387 | 0 | 2023-02-28 | MED |
Amalgamated Financial Corp. | Investment Advisor | 0.0077 | 3266 | 3266 | 2022-03-31 | |
Mackenzie Financial Corporation | Investment Advisor/Hedge Fund | 0.0027 | 1139 | -148 | 2022-09-30 | LOW |
Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 0.002 | 854 | 0 | 2021-09-30 | LOW |
Carroll Financial Associates, Inc. | Investment Advisor | 0.0008 | 339 | 0 | 2021-12-31 |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Kaleido Biosciences, Inc. Company profile
关于 Kaleido Biosciences Inc.
Kaleido Biosciences, Inc.是一家临床阶段的医疗保健公司,致力于利用微生物组器官的潜力来治疗疾病和改善人类健康。 其微生物组代谢疗法(MMTs)旨在推动微生物组现有微生物的功能和分布,以减少或增加对微生物组群中某些细菌的代谢产物的产生。 公司还在推进一个广泛的候选微生物组的管道,有可能解决各种疾病和病人需求得不到满足的状况。 公司利用其发现和开发平台研究微生物组样本中的MMTs,以快速推进MMT候选药物在健康人和病人中的临床研究。 公司的KB195是用于治疗尿素循环障碍患者的主要MMT候选药物。 公司正在根据一项新药研究申请(IND)进行II期临床试验。
Industry: | Biotechnology & Medical Research (NEC) |
18 Crosby Dr
BEDFORD
MASSACHUSETTS 01730-1402
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。